IL6 and neoplasm: As an inflammatory cytokine from the cancer microenvironment, Interleukin-6 (IL-6) was reported to promote tumor progression via activating multiple signaling pathways, including JAK/STAT3, AKT/mTOR and Raf/MEK/ERK pathways (Kishimoto, 2005).